Genetic screening in haemolytic uraemic syndrome

Current Opinion in Nephrology and Hypertension

Volumn 12, Issue 6, 2003, Pages 653-657

  Zipfel, Peter F ^a   Neumann, Hartmut P H ^b   Józsi, Mihály ^a  

^a HANS KNÖLL INSTITUTE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

ADAMTS13; Factor H; HUS; vWF cleaving protease

Indexed keywords

AMINO ACID; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H; HEPARIN; MUTANT PROTEIN; POLYANION; PROTEIN A; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AMINO ACID SUBSTITUTION; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CHROMOSOME 9Q; DISEASE ASSOCIATION; DISEASE MARKER; EFFECTOR CELL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FUNCTION; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; GENETIC LINKAGE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SCREENING; HEMOLYTIC UREMIC SYNDROME; HEREDITY; HETEROZYGOSITY; HUMAN; INFECTION; MICROANGIOPATHY; MOLECULAR RECOGNITION; MOLECULE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; REGISTER; REGULATORY MECHANISM; REVIEW; STRESS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

COMPLEMENT FACTOR H; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MUTATION;

EID: 0442307758     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200311000-00014     Document Type: Review

References (54)

1. Thompson RA, Winterborn MH. Hypocomplementaemia due to a genetic deficiency of β1H globulin. Clin Exp Immunol 1981; 46:110-119.
2. Roodhooft AM, Mclean RH, Elst E, Van Acker KJ. Recurrent haemolytic uraemic syndrome and acquired hypomorphic variant of the third component of complement. Pediatr Nephrol 1990; 4:597-599.
3. Berns JS, Kaplan BS, Mackow RC, Hefter LG. Inherited hemolytic uremic syndrome in adults. Am J Kidney Dis 1992; 19:331-334.
4. Pichette V, Querin S, Schurch W, et al. Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994; 24:936-941.
5. Rougier N, Kazatchkine MD, Rougier JP, et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998; 9:2318-2326.
6. Ohali M, Shalev H, Schlesinger M, et al. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr Nephrol 1998; 12:619-624.
7. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53:836-844.
8. Noris M, Ruggenenti P, Perna A, et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 1999; 10:281-293.
9. Ying L, Katz Y, Schlesinger M, et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 1999; 65:1538-1546.
10. Warwicker P, Donne RL, Goodship JA, et al. Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrol Dial Transplant 1999; 14:1229-1233.
11. Buddles MR, Donne RL, Richards A, et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 2000; 66:1721-1722.
12. Landau D, Shalev H, Levy-Finer G, et al. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 2001; 138:412-417.
13. Caprioli J, Bettinaglio P, Zipfel PF, et al. The molecular basis of familial haemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001; 12:297-307.
14. Pérez-Caballero D, González-Rubio C, Gallardo ME, et al. Clustering of missence mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001; 68:478-484.
15. Richards A, Buddles MR, Donne RL, et al. Factor H mutations in haemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 2001; 68:485-490.
16. Berner R, Krause MF, Gordjani N, et al. Hemolytic uremic syndrome due to an altered factor H triggered by neonatal pertussis. Pediatr Nephrol 2002; 17:190-192.
17. Neumann HPH, Salzmann M, Bohnert-Iwan B, et al. Hemolytic uremic syndrome and mutations of the factor H gene. J Med Gene 2003; 40:676-681. This is the first report describing the frequency of factor H gene mutations in a large registry of over 111 adult patients with atypical HUS.
18. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-1584.
19. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413:488-494.
20. Ajzenberg N, Denis CV, Veyradier A, et al. Complete defect in vWF-cleaving protease activity associated with increased shear-induced platelet aggregation in thrombotic microangiopathy. Thromb Haemost 2002; 87:808-811.
21. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorhisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002; 99:11902-11907.
22. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100:4033-4039.
23. Dong JF, Moake JL, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003; 278:29633-29639. This is the first report of ADAMTS13 activity on vWF multimers under physiological conditions. It locates the site on vWF for ADAMTS13 binding.
24. Assink K, Schiphorst R, Allford S, et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003; 63:1995-1999.
25. Veyradier A, Brivet F, Wolf M, et al. Total deficiency of specific von Willebrand factor-cleaving protease and recovery following plasma therapy in one patient with hemolytic-uremic syndrome. Hematol J 2001; 2:352-354.
26. Hunt BJ, Lämmle B, Nevard CHF, et al. Von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 2001; 85:975-978.
27. Remuzzi G, Galbusera M, Noris M, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002; 100:778-785. This is the first paper to show involvement of vWF cleaving protease ADAMTS13 in haemolytic uraemic syndrome.
28. Veyradier A, Obert B, Haddad E, et al. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr 2003; 142:310-317. This is the first paper to show involvement of ADAMTS13 in haemolytic uraemic syndrome in children. It describes a multicenter paediatric study.
29. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102:60-68.
30. Taylor CM. Complement factor H and the haemolytic uraemic syndrome. Lancet. 2001; 358:1200-1202.
31. Warwicker P, Goodship JA, Goodship TH. Factor H-US? Nephrol Dial Transplant 1998; 13:1921-1923.
32. Zipfel PF. Hemolytic uremic syndrome: how do factor H mutants mediate endothelial damage? Trends Immunol 2001; 22:345-348.
33. Manuelian T, Hellwage J, Meri S, et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111:1181-1190. These authors give a detailed view about the functional consequence of three mutated factor H proteins and provide a functional link between factor H mutations and microvascular damage.
34. Sánchez-Corral P, Pérez-Caballero D, Huarte O, et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 2002; 71:1285-1295. This elegant study identified mutated factor H protein associated with HUS. Covalent attachment of albumin to a mutant factor H and a decreased binding affinity to surface attached C3b was identified.
35. Hegasy GA, Manuelian T, Hogasen K, et al. The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion. Am J Pathol 2002; 161:2027-2034. This work identifies two non-framework mutations in the pig factor H protein, which cause a block in protein secretion and consequently an intracellular accumulation of the mutant protein.
36. Ault BH, Schmidt BZ, Fowler NL, et al. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 1997; 272:25168-25175.
37. Zipfel PF, Hellwage J, Friese MA, et al. Factor H and disease: a complement regulator affects vital body functions. Mol Immunol 1999; 36:241-248.
38. Friese MA, Hellwage J, Jokiranta TS, et al. FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated. Mol Immunol 1999; 36:809-818.
39. Devine DV, Rosse WF. Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H. Proc Natl Acad Sci U S A 1987; 84:5873-5877.
40. Pangburn MK. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J Immunol 2002; 169:4702-4706. This study identified for the C-terminus of factor H a central role in discrimination between activator and non-activator surfaces.
41. Hellwage J, Jokiranta TS, Friese MA, et al. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J Immunol 2002; 169:6935-6944. This article provides a structural model for the C-terminal SCR 20 domain of factor H and identifies amino acid residues which are involved in the interaction with heparin as well as C3d interaction.
42. DiScipio RG, Daffern PJ, Schraufstatter IU, Sriramarao P. Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). J Immunol 1998; 160:4057-4066.
43. Fedarko NS, Fohr B, Robey PG, et al. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000; 275:16666-16672.
44. Pio R, Martinez A, Unsworth EJ, et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 2001; 276:12292-12300.
45. Jain A, Karadag A, Fohr B, et al. Three SIBLINGS (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 2002; 277:13700-13708.
46. Martinez A, Pio R, Zipfel PF, Cuttitta F. Mapping of the adrenomedullin-binding domains in human complement factor H. Hypertens Res 2003; 26 (Suppl):S55-S59.
47. Jokiranta TS, Solomon A, Pangburn MK, et al. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 1999; 163:4590-4596.
48. Hogasen K, Jansen JH, Mollnes TE, et al. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995; 95:1054-1061.
49. Pickering MC, Cook HT, Warren J, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31:424-428. This describes the first factor H knockout mouse, which might be useful to assay the disease-associated role of the protein.
50. Aslam M, Perkins SJ. Folded-back solution structure of monomeric factor H of human complement by synchrotron X-ray and neutron scattering, analytical ultracentrifugation and constrained molecular modelling. J Mol Biol 2001; 309:1117-1138.
51. Perkins SJ, Gilbert HE, Aslam M, et al. Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. Biochem Soc Trans 2002; 30:996-1006. This is a very good summary of the molecular structural constraints of factor H domains and an up-to-date review on previous structural work of intact serum derived factor H.
52. Perkins SJ, Goodship TH. Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding site. J Mol Biol 2002; 316:217-224.
53. Gerber A, Kirchhoff-Moradpour AH, Obieglo S, et al. Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality. Pediatr Nephrol 2003; 18:952-955.
54. Antoine G, Zimmermann K, Plaimauer B, et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol 2003; 120:821-824. This report describes a novel approach to treat ADAMTS13 deficient patient.